SDC2 and colorectal carcinoma: The sensitivities of methylated SEPT9 alone, methylated SDC2 alone, and ColoDefense test for all stage CRC were 82.1% (95% CI: 73.6%‐88.3%), 69.2% (95% CI: 59.9%‐77.3%), and 88.9% (95% CI: 81.4%‐93.7%) with specificities of 95.8% (95% CI: 91.2%‐98.1%), 95.8% (95% CI: 91.2%‐98.1%), and 92.8% (95% CI: 87.4%‐96.0%), respectively.